bioRxiv ScienceSearch

Biology subjects

Santos, L. C.

Publications and source records attributed to Santos, L. C..

2 recordsLinked to original sources

Origins of fractional control in regulated cell death

Individual cells in clonal populations often respond differently to environmental changes; for binary phenotypes, such as cell death, this can be measured as a fractional response. These types of responses have been attributed to cell-intrinsic stochastic processes and variable abundances of biochemical constituents, such as proteins, but the influence of organelles has yet to be determined. We use the response to TNF-related apoptosis inducing ligand (TRAIL) and a new statistical framework for determining parameter influence on cell-to-cell variability through the inference of variance explained, DEPICTIVE, to demonstrate that variable mitochondria abundance correlates with cell survival and determines the fractional cell death response. By quantitative data analysis and modeling we attribute this effect to variable effective concentrations at the mitochondria surface of the pro-apoptotic protein Bax. Further, we demonstrate that inhibitors of antiapoptotic Bcl-2 family proteins, used in cancer treatment, may increase the diversity of cellular responses, enhancing resistance to treatment.

systems biology

An Integrated Mechanistic Model of Pan-Cancer Driver Pathways Predicts Stochastic Proliferation and Death

Most cancer cells harbor multiple drivers whose epistasis and interactions with expression context clouds drug sensitivity prediction. We constructed a mechanistic computational model that is context-tailored by omics data to capture regulation of stochastic proliferation and death by pan-cancer driver pathways. Simulations and experiments explore how the coordinated dynamics of RAF/MEK/ERK and PI-3K/AKT kinase activities in response to synergistic mitogen or drug combinations control cell fate in a specific cellular context. In this context, synergistic ERK and AKT inhibitor-induced death is likely mediated by BIM rather than BAD. AKT dynamics explain S-phase entry synergy between EGF and insulin, but stochastic ERK dynamics seem to drive cell-to-cell proliferation variability, which in simulations are predictable from pre-stimulus fluctuations in C-Raf/B-Raf levels. Simulations predict MEK alteration negligibly influences transformation, consistent with clinical data. Our model mechanistically interprets context-specific landscapes between driver pathways and cell fates, moving towards more rational cancer combination therapy.

systems biology